CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

Tamasine Stewart, Sean McKeague, Divya Somasekharannair, Lei‐Shong Lau, Ashley Whitechurch, Joshua Casan, Neil Came, Kylie Baldwin, Vuong Nguyen, Ing Soo Tiong, Sean Harrop, Mary Ann Anderson, John F. Seymour, David Westerman, Philip A. Thompson, Kah Lok Chan
British Journal of Haematology · Wiley · 2026-11-16 · DOI: 10.1111/bjh.70948

Аннотация

Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20‐negative CLL in patients treated with fixed‐duration venetoclax/obinutuzumab (Ven‐O) or venetoclax/rituximab (Ven‐R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T‐cell controls was less than 0.5. Of 60 patients, (34 Ven‐O, 26 Ven‐R), 6 demonstrated pre‐therapy CD20 negativity (1 treatment‐naïve, 5 pre‐treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post‐therapy CD20 loss (4 Ven‐O, 6 Ven‐R). Notch receptor 1 ( NOTCH1 ) variants were identified in 5/10 (50%) patients with CD20‐negative MRD, compared to 3/18 (17%) with CD20‐positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20‐negative disease long after antibody exposure (follow‐up 12–39 months). These results have potential implications for future treatment selection and efficacy.

Читать у издателя →

Похожие статьи